Therapeutics and Clinical Risk Management, 2015 Yolande B Saab,1 Rony Zeenny,2 Wijdan H Ramadan2 1School of Pharmacy, Pharmaceutical Sciences Department, 2School of Pharmacy, Pharmacy Practice Department, Lebanese American University, Byblos, Lebanon Purpose: Response to clopidogrel varies widely with
Saab YB, Zeenny R, Ramadan WH
doaj +1 more source
Clopidogrel resistance: The way forward [PDF]
Indian Heart Journal, 2014 Clopidogrel, a second generation thienopyridine has been the mainstay of ACS (Acute Coronary Syndrome) treatment for more than a decade. Clopidogrel Resistance has been associated with increased mortality in ACS patients with an increase in number of ...
Shuvanan Ray
doaj +2 more sources
Therapeutics and Clinical Risk Management, 2015 Zhi-Yu Wang,1 Meng Chen,1 Ling-Ling Zhu,2 Lu-Shan Yu,3 Su Zeng,3 Mei-Xiang Xiang,4 Quan Zhou1 1Department of Pharmacy, 2VIP Care Ward, Division of Nursing, the Second Affiliated Hospital, School of Medicine, 3Department of Pharmaceutical Analysis and ...
Wang ZY +6 more
doaj +1 more source
A novel method of thrombelastograph analysis aids assessment of antiplatelet therapy in percutaneous coronary intervention. [PDF]
, 2010 MD (Research)Background A near-patient test of responses to antiplatelet therapy would be of great value in percutaneous coronary intervention (PCI). However, at present, there are no widely accepted tests and varied definitions of “resistance”.
Hobson, Alex
core +4 more sources
Current status and future perspectives of platelet function-guided precision antiplatelet therapy for patients with cerebral infarction. [PDF]
NeuroprotectionAntiplatelet agents target the cyclooxygenase‐1 (COX‐1)/thromboxane A2 (TXA2) and adenosine diphosphate (ADP)‐P2Y12 (cytochrome P450 2C19 [CYP2C19]‐metabolized) platelet activation pathways, resulting in either drug resistance or over‐inhibition. The individualized therapeutic window balances ischemic risk (triggered by high on‐treatment platelet ...
Zhu G +7 more
europepmc +2 more sources
Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC) [PDF]
, 2018 The P2Y12 receptor inhibitor clopidogrel is widely used in patients with acute coronary syndrome, percutaneous coronary intervention, or ischemic stroke.
International Clopidogrel Pharmacogenomics Consortium
core +3 more sources
Drug interactions and hepatotoxicity of clopidogrel [PDF]
, 2010 Clopidogrel (Plavix¨) is an antiplatelet drug, which is clinically used in combination with aspirin to reduce cardiovascular events in patients undergoing percutaneous coronary intervention or in patients suffering from acute coronary syndromes ...
Zahno, Anja-Christina
core +1 more source
Giant abdominal hematoma from injection into an insulin ball during dual antithrombotic and corticosteroid therapy. [PDF]
J Diabetes InvestigJournal of Diabetes Investigation, EarlyView.
Tanji Y, Komamura H, Mita T, Sawada S.
europepmc +2 more sources
Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction--a hospital registry-primary care linked cohort (MINAP-GPRD). [PDF]
, 2011 AIMS: Adherence to evidence-based treatments and its consequences after acute myocardial infarction (MI) are poorly defined. We examined the extent to which clopidogrel treatment initiated in hospital is continued in primary care; the factors predictive ...
Van Staa, Tjeerd; id_orcid +25 more
core +1 more source
European Journal of Medical Research, 2010 Background Dual therapy with aspirin and clopidogrel increases the risk of gastrointestinal bleeding. Therefore, co-therapy with a proton pump inhibitor (PPI) is recommended by most guidelines.
Kenngott S +6 more
doaj +1 more source